Harnessing Next-Generation 3D Cancer Models to Elucidate Tumor-Microbiome Crosstalk.

Area of Science:

• Oncology
• Microbiology
• Bioengineering

Background:

• The tumor microenvironment (TME) is a complex ecosystem where the microbiome significantly impacts cancer progression, immune response, and treatment efficacy across various cancer types.
• Bacterial communities and their metabolites influence tumor behavior, inflammation, and drug resistance, necessitating advanced research models.

Purpose of the Study:

• To review recent advancements in 3D in vitro models for studying host-microbiome-tumor interactions in cancer.
• To highlight the capabilities of these models in mimicking physiological conditions and facilitating the investigation of complex biological crosstalk.

Main Methods:

• Utilizing advanced 3D in vitro models such as spheroids, organoids, organ-on-a-chip platforms, and 3D-bioprinted constructs.
• Incorporating live bacteria, metabolites, and immune components into these models to simulate the tumor-microbiome axis.
• Exploring organ-specific applications, hydrogel-based extracellular matrix mimics, and biofabrication techniques.

Main Results:

• 3D models provide spatial organization and co-culture capabilities crucial for studying tumor-microbiome cross-talk.
• These platforms enable investigation into how the microbiome influences cancer progression, immune evasion, and therapeutic resistance.
• Recent developments focus on mimicking tissue architecture and incorporating biological components for greater physiological relevance.

Conclusions:

• Evolving 3D platforms are powerful tools for microbiome-informed cancer modeling, offering significant promise for advancing therapeutic screening.
• Addressing challenges like microbiome viability and immune complexity in these models is crucial for future progress.
• Interdisciplinary collaboration between bioengineering, microbiology, and oncology is essential for developing and utilizing these advanced models effectively in precision oncology.